Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 70.12$. Average daily volumn in 3 months 8.18M. Market cap 145.78B

Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 69.31$. Total volume : 8.75M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price

Previous Close68.20
Day Range68.37-69.38
Bid69.26 x 1.1k
Ask69.30 x 1.8k
Average Volume8.18M
Market Cap145.78B
52 Week Range65.28-81.44
Trailing P/E23.49
Foward P/E8.44
Dividend (Yield %)3.29%
Ex-Dividend Date2023-01-05

Financial Details

According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2022 were 46.16B an decrease(0%) over the years 2021 revenue that were of 46.38B. In 2022 the company's total earnings were 6.33B while total earnings in 2021 were 6.99B(0%).

Loading ...


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myelom... a; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
Total Assets:
Total Cash:

News about "Bristol-Myers Squibb Company"

Bristol-Myers Squibb Company (NYSE:BMY) Currently -17.49% Below Its 52-Week High But The Downside Potential May Surprise You

Source from : marketingsentinel - 1 days ago

In last trading session, Bristol-Myers Squibb Company (NYSE:BMY) saw 8.95 million shares changing hands with its beta currently measuring 0.44. Companyโ€™s recent per share price level of $69.31 trading ...See details»


Unusual Put Option Trade in Bristol-Myers Squibb (BMY) Worth $726.85K

Source from : MSN - 1 days ago

(This description is provided by the company.) Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients ...See details»

Bristol-Myers Squibb Company (BMY) Stock: A Guide to the Market Trend

Source from : newsheater - 1 days ago

BMY stock has gone up by 1.82%, with a monthly decline of -1.67% and a quarterly plunge of -5.26%. The volatility ratio for the week is 1.09%, and the volatility levels for the last 30 days are 1.67% ...See details»


Unusual Call Option Trade in Bristol-Myers Squibb (BMY) Worth $534.73K

Source from : Fintel on MSN - 2 days ago

ET an unusually large $534.73K block of Call contracts in Bristol-Myers Squibb (BMY) was bought, with a strike price of $65.00 / share, expiring in 659 days (on January 17, 2025). Fintel ...See details»

Bristol-Myers Squibb Company (BMY): Sit Tight When Things Go Right

Source from : stocksregister - 2 days ago

Bristol-Myers Squibb Company (NYSE:BMY) at last check was buoying at $68.30 on Thursday, March 30, with a rise of 0.18% from its closing price on previous day. Taking a look at stock we notice that ...See details»

Bristol-Myers Squibb Company

Source from : Fortune - 3 days ago

ยฉ 2023 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...See details»


Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Source from : MarketWatch - 4 days ago

Shares of Bristol Myers Squibb Co. inched 0.19% higher to $68.20 Tuesday, on what proved to be an all-around rough trading session for the stock market, ...See details»


Should You Invest in Bristol-Myers Squibb Company (BMY) Now?

Source from : newsheater - 12 days ago

Bristol-Myers Squibb Company (NYSE: BMY) has a higher price-to-earnings ratio of 22.78x compared to its average ratio,, and the 36-month beta value for BMY is at 0.44. Analysts have varying views on ...See details»

Bristol-Myers Squibb Company (NYSE:BMY) insiders sold US$39m worth of stock suggesting impending weakness.

Source from : Yahoo - 1 month ago

Many Bristol-Myers Squibb Company (NYSE:BMY) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions ...See details»

With 78% ownership of the shares, Bristol-Myers Squibb Company (NYSE:BMY) is heavily dominated by institutional owners

Source from : Yahoo - 1 month ago

Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable to their trading decisions A total of 25 investors have a majority stake in the company ...See details»

Bristol Myers Squibb Co.

Source from : Wall Street Journal - 19 days ago

1 Day BMY 0.44% DJIA -0.28% S&P 500 -0.15% Health Care/Life Sciences -0.58% Giovanni Caforio Chairman & Chief Executive Officer Stryker Corp., Bristol Myers Squibb Co., European Federation of ...See details»

Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

Source from : Yahoo Finance - 3 days ago

announced today that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE: BMY), originally signed in 2016. The initial partnership ...See details»

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

Source from : MarketWatch - 18 days ago

Bristol Myers Squibb (NYSE: BMY) today announced meaningful progress toward its global inclusion & diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule. In ...See details»

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

Source from : Joplin Globe - 1 month ago

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.See details»